MedTrace Logo

Seroquel in Bipolar Depression Versus SSRI

NCT00119652 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 676

Last updated 2013-01-04

No results posted yet for this study

Summary

The purpose of this study is to determine whether quetiapine is effective and safe in the acute treatment of bipolar depression and whether the effect is maintained when treatment is continued.

Conditions

Interventions

DRUG

quetiapine fumarate (Seroquel)

DRUG

paroxetine

BEHAVIORAL

mood stabilizing activity

Sponsors & Collaborators

Principal Investigators

  • AstraZeneca Seroquel Medical Science Director, MD · AstraZeneca

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Completion
2007-05-31

Countries

  • United States
  • Australia
  • Chile
  • Colombia
  • Costa Rica
  • Greece
  • Mexico
  • Peru
  • Romania
  • South Africa
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00119652 on ClinicalTrials.gov